Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Exploring KPV Peptide and Inflammation - Core Peptides

Exploring KPV Peptide and Inflammation Jul 19, 2024 Image 1: Chemical structure of KPV Peptide In 1989, a study(2) explored the isolation and biological potential of the KPV tripeptide. Upon identifying the COOH terminal peptide in the α-MSH hormone as the pri

By Recovery & Performance Peptides Editorial Team

Exploring KPV Peptide and Inflammation

Jul 19, 2024

Image 1: Chemical structure of KPV Peptide

In 1989, a study(2) explored the isolation and biological potential of the KPV tripeptide. Upon identifying the COOH terminal peptide in the α-MSH hormone as the primary amino acid messenger sequence, scientists conducted preliminary research to determine if KPV might prevent excessive vasopermeability and swelling of blood vessels. Researchers isolated the KPV peptide and presented it to the experimental mice to assess its potential to mitigate ear swelling. The study concluded that the isolated fragment appeared to inhibit swelling. KPV’s potential anti-inflammatory action may be induced by inactivating inflammatory pathways and possibly inhibiting the synthesis and release of pro-inflammatory cytokines in intestinal and immune cells.

Research

KPV Peptide and Effects on Intestine

As part of a research study,(3) inflamed cells were isolated and exposed to either the KPV peptide or a control. Examination of the cells indicated that even nanomolar concentrations of the peptide appeared to produce anti-inflammatory effects. Researchers suggested that the peptide’s action might be mediated through PepT1 expression in these intestinal cells, implicating PepT1 in transporting the peptide to inflammation sites.

Another study(4) investigated KPV’s potential in addressing ulcerative inflammation of colonic mucosa cells. Researchers hypothesized that KPV might mitigate inflammatory responses within colonic cells by promoting mucosal healing and reducing inflammation. The proposed mechanism involved targeted delivery of KPV to inflamed colonic tissues, where it might exert anti-inflammatory influence. The findings suggested that KPV may protect mucosal surfaces and downregulate TNF-α, a key inflammatory marker.

Further trials(5) using two murine models of intestinal inflammation reported significant improvements following KPV exposure, including earlier recovery, significant weight regain, and reduced inflammatory infiltrates in colonic tissue. These outcomes were supported by a notable decrease in myeloperoxidase (MPO) activity, indicating reduced neutrophil accumulation and inflammation. Additionally, the study explored whether KPV’s anti-inflammatory actions might be linked to the melanocortin-1 receptor (MC1R), leading the researchers to suggest that these effects may be “at least partially independent of MC1R signaling.”

A 1984 study(6) aimed to evaluate the potential antipyretic action of KPV. Rabbits were given the peptide to examine its effects on the nervous system. The results suggested that KPV exhibited antipyretic potential, reducing the rabbits’ body temperature to optimal levels.

KPV Peptide and Intestinal Protection

A study(7) conducted on murine models investigated the potential of KPV peptide in mitigating intestinal inflammation. In this experiment, mice with induced bowel dysfunction were divided into two groups: one receiving the peptide and the other receiving a control. The results indicated that mice exposed to the peptide exhibited a reduction in inflammatory cells and anti-enzymatic symptoms.

Another study on a murine model of intestinal inflammation involved exposure to a chemical-induced compound of KPV and hyaluronic acid. This compound aimed to facilitate the targeted delivery of KPV to specific intestinal locations. The findings indicated a reduction in intestinal swelling, suggesting the peptide’s potential influence in reducing inflammation.

KPV Peptide and Anti-Inflammatory Characteristics

A comparative study(8) was conducted to evaluate the effects of α-MSH and KPV peptides on organ inflammation. In this experiment, mice with induced ear swelling due to skin rashes and dermatitis were divided into two groups. One group received an irritant to induce ear swelling followed by exposure to KPV peptide, while the other group received the irritant followed by α-MSH. After 24 hours, both groups showed similar improvement in reducing ear swelling. After two weeks, researchers ceased exposure to both compounds and continued presenting only the irritant.

The results indicate that the mice exposed to α-MSH continued to exhibit reduced swelling. Researchers noted that, “most of the anti‐inflammatory activities of α‐MSH can be attributed to its C‐terminal tripeptide KPV.”

Mechanisms of Wound Healing and Potential Role of KPV Peptide

Wound healing is a complex biological process involving three main phases: inflammation, proliferation, and remodeling of skin, tissues, or cells. This process is characterized by the presence of various cell types and concentrations of cytokines at the site of injury. Most cells involved in wound healing express the melanocortin 1 receptor (MC1R), where the α-MSH hormone binds. Researchers suggest that analogs of α-MSH, such as the KPV peptide, may also interact with these receptors.(8)

In another study(9) focusing on corneal epithelial wound healing, the potential of KPV peptide was investigated, particularly in relation to nitric oxide (NO) involvement. Following mechanical abrasion to induce damage to the corneal epithelium, varying concentrations of KPV peptide were applied to the tissue. The progress of epithelial wound healing was meticulously monitored and analyzed using computerized software, comparing the mean area of epithelial defects among experimental groups at multiple time points.

The findings indicated a potential acceleration in the healing process of corneal tissues exposed to KPV peptide compared to controls. Specifically, within 60 hours, all corneas exposed to KPV appeared to exhibit complete re-epithelialization, contrasting with the control group where none achieved full healing within the same timeframe.

Further experiments explored the influence of nitric oxide using the inhibitor Nω-nitro-l-arginine methyl ester (l-NAME), which appeared to impede the accelerated healing effect of KPV on corneal epithelial wounds. This suggests that the positive impact of KPV on corneal epithelial wound healing may be linked to nitric oxide dynamics within the tissue.

In vitro experiments with corneal epithelial cells (RCE) exposed to different concentrations of KPV indicated increased cell viability, particularly notable at concentrations of 1 and 10 μM. These results suggest that KPV peptide might not only accelerate corneal epithelial wound healing but also stimulate cell viability, indicating a potential broader reparative role involving nitric oxide modulation.

Scar Recovery

A study was conducted to investigate the potential of KPV peptide in scar recovery using murine models.(10) Juvenile mice were divided into two groups: one group was exposed to KPV, while the other served as a control group. Thirty minutes after exposure, all mice underwent two surgical incisions of 6.5 mm width on their dorsal skin under anesthesia.

Wound healing and scar formation were assessed on days 3, 7, 40, and 60 post-incision. Observations on days 3 and 7 indicated improved skin healing in the peptide-exposed mice, potentially attributed to reduced levels of inflammatory cells such as leukocytes and mast cells. By days 40 and 60, the peptide-exposed mice exhibited smaller scar areas compared to the control group.

KPV Peptide and Tumorigenesis

Studies suggest that KPV peptide may exert inhibitory effects on tumorigenesis in a mouse model of colitis-related cancer. To explore whether KPV might inhibit carcinogenesis independently of inflammation, researchers investigated its impact in APCMin/+ mice, a genetic model prone to intestinal adenocarcinoma. Mice were given KPV for 13 weeks, during which adenomas primarily developed in the small intestine. The findings indicated that KPV did not alter the incidence of tumors in either the small intestine or the colon. However, the data suggested anti-inflammatory characteristics of KPV, as indicated by reductions in intestinal inflammation markers such as lipocalin-2. Despite this apparent anti-inflammatory effect, KPV-induced reduction in inflammation did not appear to mitigate tumor growth in this genetic model of carcinogenesis.(11)

While hereditary colon carcinoma models represent a minority of cases, they exhibit rapid tumor progression in germ-free conditions and significant baseline intestinal inflammation. Thus, although KPV exhibited some potential in attenuating inflammation across various models of colon cancer, its efficacy in suppressing carcinogenesis was limited in the stringent APCMin/+ model. Researchers concluded that “despite modest inhibition of tumorigenesis in such a rigorous model, KPV effectively mitigated inflammation in this model of inflammation-induced carcinogenesis.”

Stomach Cancer

Investigations suggest that KPV, an anti-inflammatory tripeptide transported by PepT1, may offer protective influence against stomach cancer in wild-type mice.

Researchers utilized an AOM/DSS-induced mouse model of colon cancer to assess KPV’s potential inhibitory effects on carcinogenesis. The study(11) suggested that KPV significantly reduced tumor incidence and proliferation of malignant colonic epithelial cells in a PepT1-dependent manner.

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

References:

National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 125672, L-Valine, N-(1-L-lysyl-L-prolyl).

Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989 Sep;3(11):2282-4. https://pubmed.ncbi.nlm.nih.gov/2550304/

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008 Jan;134(1):166-78. https://pubmed.ncbi.nlm.nih.gov/18061177/

Xiao, B., Xu, Z., Viennois, E., Zhang, Y., Zhang, Z., Zhang, M., Han, M. K., Kang, Y., & Merlin, D. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular therapy : the journal of the American Society of Gene Therapy, 25(7), 1628–1640. https://doi.org/10.1016/j.ymthe.2016.11.020

Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008 Mar;14(3):324-31. doi: 10.1002/ibd.20334. PMID: 18092346. https://pubmed.ncbi.nlm.nih.gov/18092346/

B. Richards, J.M. Lipton, Effect of α-MSH 11–13 (lysine-proline-valine) on fever in the rabbit, Peptides, Volume 5, Issue 4, 1984, Pages 815-817, ISSN 0196-9781, https://doi.org/10.1016/0196-9781(84)90027-5

Klaus Kannengiesser, MD, Christian Maaser, MD, Jan Heidemann, MD, Andreas Luegering, MD, Matthias Ross, MD, Thomas Brzoska, PhD, Markus Bohm, MD, Thomas A. Luger, MD, Wolfram Domschke, MD, Torsten Kucharzik, MD, Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease, Inflammatory Bowel Diseases, Volume 14, Issue 3, 1 March 2008, Pages 324–331, https://doi.org/10.1002/ibd.20334

Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008 Aug;29(5):581-602. https://pubmed.ncbi.nlm.nih.gov/18612139/

Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. 2006 Dec;83(6):1366-72. doi: 10.1016/j.exer.2006.07.014. Epub 2006 Sep 11. PMID: 16965771. https://pubmed.ncbi.nlm.nih.gov/16965771/

de Souza KS, Cantaruti TA, Azevedo GM Jr, Galdino DA, Rodrigues CM, Costa RA, Vaz NM, Carvalho CR. Improved cutaneous wound healing after intraperitoneal injection of alpha-melanocyte-stimulating hormone. Exp Dermatol. 2015 Mar;24(3):198-203. https://pubmed.ncbi.nlm.nih.gov/25431356/

Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, Han MK, Garg P, Xiao B, Merlin D. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016 May;2(3):340-357. doi: 10.1016/j.jcmgh.2016.01.006. PMID: 27458604; PMCID: PMC4957955. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957955/

Image source: National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 125672, L-Valine, N-(1-L-lysyl-L-prolyl)-. Retrieved July 14, 2024

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

Latest Blog Articles

Thymogen Potential in Immune Cell Regulation

CJC-1295 & Hexarelin Blend Potential for Growth Hormone Signaling Stimulation

Oxytocin Actions On Neuronal Circuits in Different Mammalian Research Models

Kisspeptin 45-54 Peptide Interactions with Hypothalamic and Neuronal Cells

T-31 Peptide Interactions with Cellular Aging, Renewal, and Stress Pathways

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Incorporate KPV into Your Fresno Lab's Research

For any Fresno-based laboratory beginning studies on the KPV peptide for cancer, the first and most critical step is sourcing. The integrity of your research hinges on the purity of the peptide you use. At Real Peptides, we simplify this process by providing research-grade KPV 5MG with a guaranteed purity level of over 99%, verified by third-party labs. This ensures that your experimental results are consistent, reproducible, and free from the influence of contaminants. For proper in-vitro study preparation, the lyophilized peptide must be reconstituted. We recommend using a sterile solvent like our Bacteriostatic Water to ensure stability and sterility. By starting with a foundation of verified quality, your lab is positioned to generate meaningful and reliable data in this exciting field of 2026 oncological research. Find the Right Peptide Tools for Your Lab
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Inflammatory Pathway Research and Mechanism

The core of KPV’s research literature concerns how it modulates inflammatory signaling, and two mechanistic threads define it. The first is the receptor-independent character of its activity. In murine models of intestinal inflammation, KPV retained anti-inflammatory activity even in animals lacking functional melanocortin-1 receptor signaling, indicating that its effect does not depend on that receptor (Kannengiesser et al., 2008). This directed attention away from the cell surface and toward an intracellular site of action, distinguishing KPV mechanistically from its receptor-signaling parent molecule. The second thread is how KPV enters cells and what it does once inside. Research has characterized uptake of the tripeptide through PepT1, a di- and tripeptide transporter expressed in intestinal epithelial cells and induced in immune cells during inflammation. In intestinal epithelial and immune cell research models, PepT1-mediated uptake of KPV was associated with reduced activation of pro-inflammatory signaling, including the NF-kB pathway, and with lower expression of inflammatory mediators (Dalmasso et al., 2008). Taken together with the broader review literature on alpha-MSH-derived tripeptides (Brzoska et al., 2008), this positions KPV as a small-molecule research tool for studying how a melanocortin-derived peptide can dampen inflammatory signaling from inside the cell. Throughout this work the framing is mechanistic and preclinical, what has been measured in which research models, rather than any statement about applications outside a controlled research setting. Colitis and inflammatory bowel disease appear in this literature strictly as established animal models of inflammation used to probe the mechanism, not as conditions addressed by the compound.

RESEARCH

Navigating Research: Best Practices for KPV Studies

For researchers diving into studies involving KPV, establishing best practices right from the outset is paramount. It’s not enough to simply know what is KPV; you need to know how to handle it, store it, and prepare it for optimal experimental conditions. Our team often advises clients on these crucial procedural elements, as they directly impact the validity and reproducibility of results. First, always store lyophilized KPV according to the manufacturer's recommendations, typically in a cool, dry, and dark place. Peptides are delicate molecules, and improper storage can lead to degradation, compromising their potency. When it comes to reconstitution, using high-quality Bacteriostatic Reconstitution Water (bac) is essential. This helps maintain sterility and prevents bacterial growth, which is critical for in vitro and in vivo studies. Always follow precise volumetric measurements to ensure accurate dosing. We recommend gentle swirling rather than vigorous shaking to avoid damaging the peptide structure. Lastly, careful documentation of batch numbers, reconstitution dates, and storage conditions for every KPV sample is just good science. These meticulous steps ensure that your research on what is KPV is built on a foundation of integrity and consistency, paving the way for truly reliable and impactful discoveries. It’s the small details that make the biggest difference, honestly.

POTENTIAL BENEFITS

KPV Peptide: Benefits, Dosage & Safety (2026 Guide)

KPV Peptide: Benefits, Dosage & Safety (2026 Guide) KPV peptide is an anti-inflammatory tripeptide from alpha-MSH studied for gut, skin, and inflammation. A research guide to benefits, dosage, routes, and safety. KPV peptide is a tripeptide made of lysine, proline, and valine that comes from the tail end of alpha-melanocyte-stimulating hormone (α-MSH). Researchers study it as an anti-inflammatory and antimicrobial agent that calms overactive immune signaling without shutting the immune system down. Most of the attention sits in three areas: gut inflammation, skin conditions, and whole-body inflammation driven by the NF-κB pathway. One detail sets it apart from almost every other peptide. KPV is small enough to survive the digestive tract and get absorbed intact, so it can be taken by mouth. That is rare. It also explains why so much of the published work points at the gut. This guide covers what KPV is, how it works, what the evidence supports, how it is dosed across injectable, oral, and topical forms, its safety profile, and the popular KPV plus BPC-157 pairing. A note on evidence before we start: the science here is preclinical. The findings come from cell cultures and animal models, not completed human clinical trials. What is KPV peptide? KPV is a fragment, not a full hormone. It is the last three amino acids of α-MSH, the sequence at positions 11 to 13, written as Lys-Pro-Val. Snip that tripeptide off the parent hormone and you keep most of the anti-inflammatory action…
05

Product & matchup locker

Linked catalog and comparison files.

Comparison

KPV Peptide vs Other Anti-Inflammatory Research Compounds

Researchers studying inflammatory pathways often need to compare available compounds to select the most appropriate tool for their model. The following comparison situates KPV pep…

Comparison

KPV vs. Alpha-MSH: Research Comparison

KPV and alpha-MSH are closely related but functionally distinct in ways that matter for experimental design. Size 13 amino acids 3 amino acids Receptor binding MC1R, MC3R, MC4R, M…

Comparison

Comparison of PepT1 Substrates Relevant to Research

Gly-Sar Model dipeptide High Widely used reference substrate Cephalexin Beta-lactam peptidomimetic Used in competitive inhibition assays KPV Tripeptide Moderate to high Natural se…

Continue reading

Related articles